thalidomide-o-peg-4-azide

Thalidomide-O-PEG4-azide is a PEG-based PROTAC linker utilized in PROTAC synthesis[1].

Thalidomide 4-fluoride (E3 ligase Ligand 4) (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand. Thalidomide 4-fluoride can be used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

Thalidomide-4-OH (E3 ligase Ligand 2) (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used to recruit of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) is a linker to form PROTACs

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.

Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-O-COOH (Cereblon ligand 3) is a Thalidomide-based Cereblon ligand utilized for recruiting the CRBN protein and can be linked to a protein ligand via a linker to create PROTACs.

Pomalidomide 4'-PEG2-azide is a synthetic E3 ligase ligand-linker conjugate, comprising a Pomalidomide-based cereblon ligand and a linker.

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide 4'-ether-alkylC2-amine hydrochloride (halidomide-linker 6) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-PEG4-azide is a polyethylene glycol (PEG) derivative used as a linker in the synthesis of Proteolysis Targeting Chimeras (PROTACs) [1].

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.

Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus a short PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 11 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].

N-methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy5 is a PEG-based linker compound employed in PROTAC synthesis [1].

Azide-PEG-amine (MW 3500) is a polyethylene glycol (PEG) linker compound, designed for the synthesis of proteolysis targeting chimeric molecules (PROTACs)[1].

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].

Azide-PEG-azide (MW 20000) is a polyethylene glycol (PEG)-based linker compound used in the synthesis of Proteolysis Targeting Chimeras (PROTACs)[1].

Pomalidomide 4'-alkylC6-azide, a Pomalidomide-based cereblon (CRBN) ligand, facilitates the recruitment of CRBN protein. It is designed to attach to a protein through a linker, enabling the formation of PROTAC [1].

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11) is a Thalidomide-based synthetic E3 ligase ligand-linker conjugate, consisting of a cereblon ligand and a linker, used in the production of PROTACs (proteolysis-targeting chimeras).

Thalidomide-5-O-C2-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and can be conjugated via a linker to form PROTACs [1].

Thalidomide-5-O-C4-NH2 hydrochloride, a cereblon ligand derived from Thalidomide, facilitates the recruitment of CRBN protein. It can be tethered to a ligand for protein recruitment through a linker, enabling the formation of PROTACs [1].

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC1-PEG3-alkylC3 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that combines a cereblon ligand derived from Thalidomide with a linker used in PROTAC technology.

Thalidomide-O-amido-C3-COOH is a synthesized conjugate of an E3 ligase ligand-linker compound that combines a cereblon ligand (derived from Thalidomide) with a linker commonly employed in PROTAC technology.

m-PEG-azide (MW 10000), a PEG-based linker for PROTACs, joins two essential ligands crucial for forming PROTAC molecules, enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Thalidomide-O-PEG4-amine is a PEG-based PROTAC linker used in the synthesis of PROTACs [1].

m-PEG-azide (MW 2000) is a PEG-based linker used in PROTACs to join two essential ligands, facilitating the selective degradation of target proteins through the ubiquitin-proteasome system within cells.

m-PEG-azide (MW 5000) is a PEG-based linker for PROTACs, facilitating the conjugation of two essential ligands to enable selective protein degradation via the ubiquitin-proteasome system in cells.

Thalidomide-5-O-C14-NH2 hydrochloride, a cereblon ligand based on Thalidomide, facilitates the recruitment of CRBN protein. By incorporating a linker, this compound can be conjugated to a ligand to create PROTACs [1].

Thalidomide-O-C8-COOH, also known as Cereblon ligand 3, is a Thalidomide-derived compound that serves as a Cereblon (CRBN) ligand for the targeted recruitment of CRBN protein. It can be coupled via a linker to another ligand to create proteolysis-targeting chimeras (PROTACs)[1].

Thalidomide-4-O-C12-NH2 hydrochloride is a cereblon ligand derived from Thalidomide, used to recruit the CRBN protein. It can be linked to a protein ligand via a linker, facilitating the creation of PROTACs [1].

Thalidomide-4-O-C11-NH2 hydrochloride is a thalidomide-based cereblon ligand for CRBN protein recruitment, capable of conjugation to a protein ligand via a linker to create PROTACs [1].

Thalidomide 4'-ether-PEG1-azide, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein. This compound is capable of being linked to a protein ligand via a linker to construct PROTACs [1].

Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).

Thalidomide-O-C8-NH2 is a chemically synthesized conjugate that combines a cereblon ligand derived from Thalidomide with a linker utilized in PROTAC technology. It functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate combining a Thalidomide-based cereblon ligand with a (PROTAC) technology linker, acting as an E3 ligase ligand-linker conjugate to enable targeted protein degradation.

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand based on Thalidomide and a linker component commonly used in PROTAC technology.